KUALA LUMPUR: Duopharma Biotech Bhd
has entered into a deal to supply the Ministry of Health with 6.4 million doses of Covid-19 vaccine developed by Russia.
The supply is subject to the “Sputnik V” vaccine being approved by Drug Control Authority, Malaysia through technical evaluation by the National Pharmaceutical Regulatory Agency.
Duopharma told Bursa Malaysia today that it has signed two separate term sheet agreements for the project.
The first is with the Russian Direct Investment Fund (RDIF) to secure the 6.4 million doses of Sputnik V.
Sputnik V, developed by Russia's Gamaleya National Research Institute of Epidemiology and Microbiology, is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform.
Duopharma said RDIF and Gamaleya Institute are also exploring towards further collaboration to enhance Duopharma's capabilities in research and development, technology transfer, local manufacturing, and supply of the vaccine to Malaysia and other Asean countries.
The second term sheet agreement was with the Ministry of Health to supply 6.4 million doses to vaccinate 3.2 million Malaysians.
"Supply of the Sputnik V vaccine will be in phases over a period within 2021," Duopharma said.
Apart from the relevant approvals, Duopharma said the supply contract is also subject to the execution of the definitive supply agreements with RDIF, as well as with MOH.
Did you find this article insightful?
82% readers found this article insightful
